Small-business device fee relief comes with hidden tariff on imports

What it does

This bill amends the Federal Food, Drug, and Cosmetic Act to expand the small business waiver from FDA device registration fees. It redefines 'small business' as entities with fewer than 20 full-time employees (down from a higher threshold), grants a 3-year 100% fee waiver followed by a 2-year 50% waiver to qualifying small businesses, and bars foreign-owned companies from claiming the waiver while imposing an 8× fee multiplier on foreign establishments. The bill also prohibits the FDA from considering past non-payment when evaluating waiver eligibility.

Why we flagged it

The bill's core mechanism is a cost waiver for small domestic device manufacturers—a regulatory relief measure. However, the 8× fee on foreign competitors and the non-reviewability clause suggest a secondary protectionist and accountability-limiting intent that extends beyond simple small-business support.

• Section 3 imposing 8× fee multiplier on foreign establishments is substantively unrelated to small-business fee relief and functions as a tariff-like trade barrier.

What the text implies

• The 8× fee on foreign device manufacturers may increase import costs, potentially raising prices for consumers dependent on foreign-sourced medical devices and reducing competition in the U.S. market.
• The non-reviewability clause (Section 2(5)) removes judicial review of FDA waiver denials, preventing small businesses from challenging arbitrary or discriminatory denials in court.
• The 60-day advance notice requirement and income-tax-return submission may create a compliance burden that disproportionately affects very small or informal operations.
• The 5-year waiver expiration creates a cliff effect: after 5 years, small businesses lose all fee relief and must pay full fees, potentially forcing some out of the market.
• Foreign companies cannot restructure as U.S. entities to claim the waiver, effectively creating a citizenship-based subsidy that may violate trade agreements or WTO principles.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Small domestic manufacturers and device makers gain meaningful cost relief—a concrete public benefit if it encourages market entry and competition in medical devices. However, the 8× fee on foreign establishments may increase costs for imported devices and could be passed to consumers; the non-reviewability clause also removes judicial oversight of waiver denials, reducing transparency and accountability.

Who stands to gain

• small domestic medical device manufacturers
• small domestic in vitro diagnostic manufacturers
• domestic device startups and emerging competitors

Named in the bill

FDA, Small Business Administration, Federal Food, Drug, and Cosmetic Act, Section 738, Section 510, 13 CFR 121.103, 13 CFR 121.106

Where it stands

• Jul 20, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 20, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $40,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Scott Perry, the sponsor, reported $668,994 in PAC receipts in the 2026 cycle.

• Florida Memorial University — $20,000 on 1 filing
• Virginia Union University — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.